22 research outputs found
Prognostic value of histopathology and trends in cervical cancer: a SEER population study-3
<p><b>Copyright information:</b></p><p>Taken from "Prognostic value of histopathology and trends in cervical cancer: a SEER population study"</p><p>http://www.biomedcentral.com/1471-2407/7/164</p><p>BMC Cancer 2007;7():164-164.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC1994954.</p><p></p>rtical axes are scaled to highlight the trend within each histopathological type
Prognostic value of histopathology and trends in cervical cancer: a SEER population study-1
<p><b>Copyright information:</b></p><p>Taken from "Prognostic value of histopathology and trends in cervical cancer: a SEER population study"</p><p>http://www.biomedcentral.com/1471-2407/7/164</p><p>BMC Cancer 2007;7():164-164.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC1994954.</p><p></p>ing into account registry area, age, year of diagnosis, race, marital status, grade, stage, surgery and radiotherapy, for a theoretical patient presenting with average characteristics of the population
Prognostic value of histopathology and trends in cervical cancer: a SEER population study-0
<p><b>Copyright information:</b></p><p>Taken from "Prognostic value of histopathology and trends in cervical cancer: a SEER population study"</p><p>http://www.biomedcentral.com/1471-2407/7/164</p><p>BMC Cancer 2007;7():164-164.</p><p>Published online 23 Aug 2007</p><p>PMCID:PMC1994954.</p><p></p>rtical axes are scaled to highlight the trend within each histopathological type
Unadjusted breast-cancer mortality as a function of the percentage of involved nodes in T1–T2 breast cancer based on the SEER (Surveillance, Epidemiology, and End Results) program data
<p><b>Copyright information:</b></p><p>Taken from "Ratios of involved nodes in early breast cancer"</p><p>Breast Cancer Research 2004;6(6):R680-R688.</p><p>Published online 6 Oct 2004</p><p>PMCID:PMC1064081.</p><p>Copyright © 2004 Vinh-Hung et al.; licensee BioMed Central Ltd</p> Dot size computed as a step function of the number of patients at risk: smallest dots 1–20 patients and the largest dots >200 patients. The straight line highlights the trend but should not be interpreted as the basis for extrapolation
Unadjusted breast cancer mortality as a function of the estimated log odds of nodal involvement in T1–T2 breast cancer
<p><b>Copyright information:</b></p><p>Taken from "Ratios of involved nodes in early breast cancer"</p><p>Breast Cancer Research 2004;6(6):R680-R688.</p><p>Published online 6 Oct 2004</p><p>PMCID:PMC1064081.</p><p>Copyright © 2004 Vinh-Hung et al.; licensee BioMed Central Ltd</p> Red dots are node-negative patients, and blue are node-positive patients. The smallest dots represent 1–20 patients and the largest dots represent >200 patients. The straight lines highlight the different slopes but should not be interpreted as the basis for extrapolation (they would extrapolate to 100% mortalities)
Joint effect of the numbers of involved nodes (npos) and uninvolved nodes (nneg) on survival in T1–T2 breast cancer
<p><b>Copyright information:</b></p><p>Taken from "Ratios of involved nodes in early breast cancer"</p><p>Breast Cancer Research 2004;6(6):R680-R688.</p><p>Published online 6 Oct 2004</p><p>PMCID:PMC1064081.</p><p>Copyright © 2004 Vinh-Hung et al.; licensee BioMed Central Ltd</p> Part of the contour plot was partially filled at the corners by padding. The pattern of isoprobability contours radiating from the origin suggests that similar ratios of involved/uninvolved nodes were associated with similar Kaplan–Meier survival estimates (for example. 8 npos/10 nneg has approximately the same 75% [contour line 0.75] 5-year survival chance as 4 npos/5 nneg). Reproduced with permission from Vin-Hung and coworkers [28]. Colors were omitted in the original publication
Treatment toxicity reported in studies using IMRT and chemotherapy for the treatment of locally advanced rectal cancer.
<p>Treatment toxicity reported in studies using IMRT and chemotherapy for the treatment of locally advanced rectal cancer.</p
Dose distribution to target volume and to critical organs at risk for complications following image-guided radiotherapy for head and neck cancer.
<p>PTV1: target volume receiving 66 to 70 Gy; PTV2: target volume receiving 59.6 to 63 Gy; PTV3: target volume receiving 54 to 56 Gy; Gy: gray.</p
Aspiration rate reported in the literature following radiotherapy for non-laryngeal and non-hypopharyngeal head and neck cancer.
<p>C: conventional with two lateral and a supraclavicular field; NS: not specified; IMRT: intensity-modulated radiotherapy; WF: whole-field; SF: split-field; IGRT: image-guided radiotherapy.</p